The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
 
Camilla Oliveira Hoff
Leadership - Rede D'Or São Luiz (I)
Stock and Other Ownership Interests - Oncostar (I)
Honoraria - Bayer (I); Lilly (I)
Consulting or Advisory Role - Bayer (I); Lilly (I)
Research Funding - Exelixis (I); Lilly (I); Novartis (I)
 
Daniel McGrail
Patents, Royalties, Other Intellectual Property - Pending patents on biomarkers for sensitivity to cancer therapeutics.
 
Simon Heeke
Employment - Marker Therapeutics (I)
Honoraria - Qiagen
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - Roche
 
Luana Guimaraes de Sousa
No Relationships to Disclose
 
Kaiyi Li
No Relationships to Disclose
 
Diana Bell
No Relationships to Disclose
 
Yoshitsugu Mitani
No Relationships to Disclose
 
Mario L. Marques-Piubelli
No Relationships to Disclose
 
Maria Angelica Cortez
No Relationships to Disclose
 
Shiaw-Yih Lin
No Relationships to Disclose
 
Yasir Y Elamin
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; Lilly; Sanofi; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics
Research Funding - AstraZeneca; Blueprint Medicines; Elevation Oncology; Forward; Lilly; Precision Therapeutics; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics; Xcovery
Travel, Accommodations, Expenses - Lilly
 
Adel K. El-Naggar
No Relationships to Disclose
 
Renata Ferrarotto
Consulting or Advisory Role - Ayala Pharmaceuticals; Bicara Therapeutics; Elevar Therapeutics; G1 Therapeutics; Guidepoint Global; Intellisphere; Merck Serono; Prelude Therapeutics; Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); Ayala Pharmaceuticals (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Prelude Therapeutics (Inst)